Effect of HER-2/NEU Signaling on Sensitivity to Trail in Prostate Cancer
Annual rept. 1 Jun 2005-31 May 2006
PITTSBURGH UNIV PA
Pagination or Media Count:
The long-term goal of our research project is to develop a novel therapy for HER-2neu overexpressing prostate cancer. Previous studies have shown that the HER-2neu homodimer constitutively activates the PI3K-Akt-NF-kB single transduction pathway. In this budget period, we examined whether quercetin, a P13K inhibitor, promotes TRAIL cytotoxicity by inhibiting Akt activity. As DU-145 cells were treated with quercetin, we observed that TRAIL-induced cytotoxicity was promoted.
- Medicine and Medical Research